Get started
Author

Derek J. Gyori

Observed names: Derek Gyori, Derek J Gyori
ORCID: 0000-0002-6285-4234
Observed ORCID: 0000-0002-6285-4234
OpenAlex ID: A5089800275
Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system
2024 · Alex K Bryant, Jacqueline R Lewy, et al. · The Lancet Oncology · 18
PDF
Evaluation of burnout among pharmacy residents in the United States
2025 · Derek J. Gyori, Aimrie L. Ream‐Taylor, et al. · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 3
PDF
Cancer Healthcare Utilization Impact of Precision Therapeutics: Hospitalization/Emergency Visits
2020 · Stephanie Wonnell Yencho, Jared Austin, et al. · Cancer Science & Research · 3
PDF
Evaluation of appropriate use of bisphosphonates and denosumab in patients with cancer
2019 · Derek J Gyori, Susan M Bullington, et al. · Journal of Oncology Pharmacy Practice · 3
Cancer Immunotherapy Stewardship — Cost-Neutral, Patient-Centered Dosing to Increase Infusion Center Efficiency
2026 · Julie A. Moeller, Derek J. Gyori, et al. · NEJM Catalyst · 1
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted Analysis
2026 · Garth W. Strohbehn, Molly C. Tokaz, et al. · JCO Oncology Practice
Managing Nonadherence
2026 · Sarah Aldrich Renner, Marilee Clemons, et al. · Springer eBooks
Adherence Case Studies
2026 · Brian Tasma, Marilee Clemons, et al. · Springer eBooks
Introduction of an immunotherapy stewardship program at a single VA medical center.
2025 · Isabella Gau, Julie Moeller, et al. · JCO Oncology Practice
Works count: 9
Citation count: 28
H-index: 3
I10-index: 1
Year
Topic
Type